Current Clinical Trials

For information or enquiries on the clinical trials listed below, please email clinical.trials@nccs.com.sg

Phase 1

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	NSCLC lung, PDAC / pancreatic and GC (GI)	Advanced recurrent	EBC-129-01 A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours	Dr Matthew Ng	NCT05701527	Open
2	NSCLC / lung, all solid tumours	locally advanced or metastatic / stage 4 / stage IV	NVL-520-01 A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)	Dr Daniel Tan	NCT05118789	Open
3	NSCLC / lung, all solid tumours	Advanced recurrent	NVL-655-01 A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1)	Dr Aaron Tan	NCT05384626	Open
4	Breast	Advanced, Metastatic / stage 4 / stage IV	CAAA603D12101 A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor	Dr Yap Yoon Sim	NCT06247995	Open
5	Ovarian, lung, breast, endometrial	Advanced, Metastatic / stage 4 / stage IV	PMV-586-101 A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)	Dr Tira Tan	NCT04585750	Open
6	Ovarian, Endometrial and Lung adenocarcinoma	Advanced, Metastatic / stage 4 / stage IV	ZWI-ZW191-101 A Phase 1, Open-label, Multicenter, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of a Novel Folate Receptor Alpha Inhibitor, ZW191, as Monotherapy in Participants with Advanced Solid Tumors	Dr Daniel Tan	NCT06555744	Open
7	Squamous Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Cervical Cancer	Advanced, Metastatic / stage 4 / stage IV	ALE.P02.01 A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with selected CLDN1+ solid tumors	Dr Darren Lim	NCT06747585	Open
8	all solid tumours	Advanced, Metastatic / stage 4 / stage IV	BAYER 22931 A first-in-human study to evaluate the safety, tolerability and pharmacokinetics, pharmacodynamics and preliminary clinical activity of BAY 3713372, a novel 2nd generation PRMT5 inhibitor, in participants with MTAP-deleted solid tumors.	Dr David Tai	NCT06914128	Open
9	CRC, PDAC, NSCLC, other solid tumours	Advanced, Metastatic / stage 4 / stage IV	GO45416 A PHASE I/II DOSE-ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-7035 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH ADVANCED SOLID TUMORS WITH A KRAS G12D MUTATION	Dr David Tai	NCT06619587	Open
10	all solid tumors	Advanced, Metastatic / stage 4 / stage IV	YO45758 A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activitiy of RO7673396 as a Single Agent and in Combination with Other Anticancer Therapies in patients with Advanced Solid Tumors Harboring Ras Mutation(s)	Dr David Tai	NCT06884618	Open
11	NSCLC / Lung	Advanced, Metastatic / stage 4 / stage IV	BH-30643-01 A Phase 1/2 Open-Label, Multicenter, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BH-30643 in Adult Subjects with Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (SOLARA)	Dr Darren Lim	NCT06706076	Open
12	Colorectal Cancer Intrahepatic Cholangiocarcinoma Urothelial Carcinoma Squamous Non-small Cell Lung Cancer Squamous Cervical Cancer	Advanced, Metastatic / stage 4 / stage IV	ALE.P03.01 A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with selected Advanced or Metastatic CLDN1+ solid tumors.	Dr David Tai	NCT07169734	Open
13	Breast, Gastric, Other solid tumor with HER2 amp	Advanced, Metastatic / stage 4 / stage IV	IKS014-01 A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants with Advanced HER2+ Solid Tumors	Dr Tira Tan	NCT05872295	Open
14	all solid tumours	Advanced, Metastatic / stage 4 / stage IV	GO44431 A PHASE I, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF RO7566802 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS	Dr Sophia Wong	NCT06031441	On hold
15	HR+ HER2- lobular BC, HR+ HER2- ductal BC, NSCLC, TNBC, CRC and soft tissue sarcoma	Advanced, Metastatic / stage 4 / stage IV	CGCJ904A12101 Phase I FIH dose escalation/expansion study to evaluate GCJ904 ([177Lu]Lu-DFC413), a radioligand therapy targeting FAP, as a single agent in multiple indications	Dr Aaron Tan	NCT07261631	Open
16	breast all solid tumors	Advanced, Metastatic / stage 4 / stage IV	CGVV858A12101 An open-label, multi-center, phase I/II study of CDK inhibitors as a single agent and in combination with endocrine therapy in patients with advanced HR+HER2- breast cancer and other advanced solid tumors	Dr Tira Tan	NCT07288359	Open
17	Colon	Advanced, Metastatic / stage 4 / stage IV	BAY 23111-1 An open-label multi-cohort study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BAY 3771249 as monotherapy and in combination with cetuximab in participants with metastatic colorectal adenocarcinoma harboring a KRAS G12D mutation	Dr David Tai	NCT07535112	Open
18	Urothelial, biliary tract, Uterine, cervical, non-sqamous NSCLC, salivary gland, colorectal, all solid tumors excep for breast	Advanced, Metastatic / stage 4 / stage IV	Beamion PANTUMOR-1 A Phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed/amplified solid tumours	Dr Tira Tan	NCT06581432	Open
19	NSCLC / Lung	Mets NSCLC	HMBD-001-103 A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers	Dr Aaron Tan	NCT05910827	Open

Current clinical trials by body parts

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	Pancreas / GI/ BTC	Metastatic	D9800C00001/CLARITY-PanTumour01 A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2. (AZD0901)	Dr Matthew Ng	NCT06219941	On hold
2	Breast	Mets ER+PR+	ELEVATE A Phase II randomized trial of Endocrine therapy Letrozole and Lenvatinib versus Fulvestrant in Metastatic Estrogen Receptor positive, HER2 negative breast cancer, who have progressed on CDK4/6 inhibitors	Dr Elaine Lim	NCT05181033	Open
3	Breast	Mets HER2-/HR+ 1L Hormone resistant	CO44657 A phase III randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with Estrogen Receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy	Dr Yap Yoon Sim	NCT06065748	Open
4	Breast	PD-L1 Positive Locally Recurrent Inoperable or Metastatic TNBC	TROPION-Breast05: A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast	Dr Rebecca Dent	NCT06103864	Open
5	Breast	HR-low+/HER2-, TROP2, and PD-L1 status	MK2870-032 A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer	Dr Tira Tan	NCT06966700	Open
6	Breast	Recurrence while on adjuvant ET ≥24mos	MK5684-015 A Multicenter, Open-label, Phase 2 Basket Study of MK 5684 in Participants With Selected Solid Tumors Cohort A – Breast Cancer	Dr Jack Chan	NCT06979596	Open
7	Breast	metastatic breast cancer	ASPEN-09-03 (Substudy Protocol) A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer Cancer	Dr Rebecca Dent	NCT07007559 Substudy 3	Open
8	Colorectal	locally advanced unreseectable/ Metastatic	KANDLELIT-012 A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer	Dr Dawn Chong	NCT06997497	Open
9	Colorectal	unreseectable/ Metastatic	CA266-0003 A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cance	Dr Evelyn Wong	NCT07221357	On hold
10	Endometrial	pMMR and p53wt	MK5684-015 A Multicenter, Open-label, Phase 2 Basket Study of MK 5684 in Participants With Selected Solid Tumors Cohort C – Endometrial Cancer	Dr Jack Chan	NCT06979596	Open
11	Endometrial	Recurrent	BNT323-01 A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2-expressing recurrent endometrial cancer	Dr Chay Wen Yee	NCT06340568	On hold
12	HNSCC	recurrent, metastatic	BCA101X301 FORITFI-HN01 A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	Dr Darren Lim	NCT06788990	Open
13	HNSCC	locally advanced unresected	GSK221530 (JADE) A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma	Dr Ang Mei Kim	NCT06256588	Open
14	Liver cancer or Colorectal cancer with liver metastases / GI	Adjuvant	CA209-7R9 An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)	Dr Koo Si Lin	NCT04912765	Open
15	Liver / GI	Locally advanced	AHCC09 A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II trial to Compare the Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 resin microspheres) followed by Atezolizumab plus Bevacizumab versus Selective Internal Radiation Therapy (SIRT-Y90) followed by placebo in patients with locally advanced Hepatocellular Carcinoma	Dr Toh Han Chong	NCT05377034	Open
16	Liver / GI	Resectable HCC (high risk of recurrence)	AHCC12 Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)	Dr Toh Han Chong	NCT05516628	Open
17	Liver / GI	HCC, solid tumor with liver disease	Histotripsy Ablation for Liver Tumours (HALT): A Multi-centre Prospective Pilot Study on the Safety and Efficacy of Histotripsy in Asian Primary and Secondary Liver Malignancies	Dr Brian Goh	NCT07428356	Open
18	NSCLC / Lung	Mets NSCLC	LUNAR-2 EF-44 Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer	Dr Ng Quan Sing	NCT06216301	Open
19	NSCLC / Lung	II to IIIB (N2) NSCLC	V940-009 A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)	Dr Aaron Tan	NCT06623422	Open
20	NSCLC / Lung	Mets NSCLC	IOV-LUN-202 A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145)in Patients with Metastatic Non-Small-Cell Lung Cancer	Dr Sophia Wong	NCT04614103	Open
21	NSCLC / Lung	Mets NSCLC	M25-274 A Phase 2, Open-Label, Randomized, Global Study of Two Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer	Dr Gillianne Lai	NCT06568939	Open
22	NSCLC / Lung	Locally Advanced/ Mets NSCLC	D516KC00001 A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)	Dr Tan Wan Ling	NCT06417814	Open
23	NSCLC/Lung	Locally Advanced/ Mets NSCLC	NVL655-04 A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)	Dr Gillianne Lai	NCT06765109	Open
24	NSCLC/Lung	Locally Advanced/ Mets NSCLC	CO45042 A Phase III, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of Divarasib And Pembrolizumab Versus Pembrolizumab And Pemetrexed And Carboplatin Or Cisplatin In Patients With Previously Untreated, KRAS G12C-Mutated, Advanced Or Metastatic Non-Squamous Non−Small Cell Lung Cancer	Dr Gillianne Lai	NCT06793215	Open
25	NSCLC/Lung	Locally Advanced/ Mets NSCLC	M25-287 Non-Small Cell Lung Cancer: Telisotuzumab Adizutecan and Osimertinib Phase 2/3 Study in Previously Untreated Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation	Dr Stephanie Saw	NCT07005102	Open
26	NSCLC/Lung	Locally Advanced/ Mets NSCLC	RMC-6236-301 Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC (RASolve 301)	Dr Amit Jain	NCT06881784	Open
27	NSCLC/Lung	Locally Advanced/ Mets NSCLC	D6187C00001 A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)	Dr Daniel Tan	NCT07098338	Open
28	NSCLC/Lung	Locally Advanced/ Mets NSCLC	ARR-630-301 A Global, Phase 3, Randomized, Multicenter, Open Label Study To Evaluate The Efficacy And Safety Of Firmonertinib Compared With Osimertinib As Firstline Treatment In Participants Who Have Locally Advanced Or Metastatic Non-small-cell Lung Cancer With Epidermal Growth Factor Receptor P-loop And Alpha C-helix Compressing (PACC) Mutations (FURMO-006)	Dr Gillianne Lai	NCT07185997	Open
29	NSCLC/Lung	resectable NSCLC (stage II-IIIA)	1479-0032 Beamion LUNG-3: A randomized, controlled study of zongertinib as a monotherapy compared to standard of care in patients with resectable NSCLC (stage II-IIIA) and activating HER2 mutations	Dr Stephanie Saw	NCT07195695	Open
30	SCLC / Lung	extensive-stage small cell lung cancer	1438-0012 A Phase III multi-center, open-label, randomized trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs atezolizumab, carboplatin, and etoposide as first line of treatment in patients with extensive-stage small cell lung cancer (DAREON-Lung-1)	Dr Amanda Seet	NCT07472517	Open
31	NSCLC/ Lung	Adjuvant NSCLC	TAS6417-302 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)	Dr Gilliane Lai	NCT07128199	Open
32	NSCLC / Lung	Locally Advanced/ Mets NSCLC	Bayer 22615 A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations	Dr Aaron Tan	NCT06452277	Open
33	SCLC / Lung	Extensive stage SCLC	CDJI136A12101 A Phase I/II Open Label Study of DJI136, a DLL3-targeted CAR-T therapy, in Adult Patients with ES-SCLC	Dr Sophia Wong	NCT07564401	Open
34	Lymphoma	relapsed/ refractory Lymphoma	POLAR Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)	Dr Lim Soon Thye	NCT06160843	Open
35	Lymphoma	untreated B-cell lymphoma	MK-2140-010 A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)	Dr Joshua Hoe	NCT06717347	On hold
36	Chronic Myeloid Leukemia	Chronic Phase	POLARIS-2 A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia	Dr Charles Chuah	NCT06423911	Open
37	Melanoma	Unresectable or metastatic	IOV-MEL-301 A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma	Dr Nagavalli	NCT05727904	Open
38	NPC	Metastatic, mets	SG-AAA-II-01 / CAAA601A0SG01T A Biomarker Enrichment Phase II study of 177Lu-DOTATATE in Metastatic Nasopharyngeal Cancer with a safety run-in	Dr Daniel Tan	NCT05198479	On hold
39	NPC	stage IIIA-IVA	RIBBON-LA-01 Single-arm, open-label, phase 2 trial of tislelizumab and metronomic capecitabine as maintenance therapy in high-risk locoregionally-advanced nasopharyngeal carcinoma	Dr Darren Lim	NCT06093061	Open
40	NPC	recurrent/metastatic	NRG-HN011 A randomized phase II study of nivolumab versus nivolumab and BMS-986016 (relatlimab) as maintenance treatment after first-line treatment with platinum-gemcitabine-nivolumab for patients with epstein-barr virus-associated recurrent/metastatic nasopharyngeal carcinoma (REMAIN)	Dr Darren Lim	NCT06029270	Open
41	Ovarian cancer	maintenance	[IIT] NIRVANA-1 A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery	Dr Jack Chan	NCT05183984	Open
42	Ovarian	advanced	MK5684-015 A Multicenter, Open-label, Phase 2 Basket Study of MK 5684 in Participants With Selected Solid Tumors Cohort B - Ovarian Cancer	Dr Jack Chan	NCT06979596	Open
43	Ovarian	maintenance	DS8201-772 A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer	Dr Soh Lay Tin	NCT06819007	Open
44	Pancreas / GI	Metastatic	LDOXIRI-PDAC-01 A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients	Dr Joycelyn Lee	NCT05929885	Open
45	Pancreas / GI	Metastatic	D9800C00001/CLARITY-PanTumour01 A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2. (AZD0901)	Dr Matthew Ng	NCT06219941	On hold
46	Pancreas / GI	Metastatic	CA240-0030 A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	Dr David Tai	NCT07076121	Open
47	Prostate	Metastatic	CAAA617D12302 An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)	Dr Jeffery Tuan	NCT05939414	Open
48	Prostate	Metastatic/ mCRPC	MK-5684-003 A Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy	Dr Ravindran Kanesvaran	NCT06136624	Open
49	Prostate	Metastatic/ mCRPC	MK5684-004 A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)	Dr Johan Chan	NCT06136650	On hold
50	Prostate	Metastatic/ mCRPC	CAAA817A12201 A phase II/III, open-label, international, multi-center, randomized study of AAA817 versus best standard of care in the treatment of adult participants with PSMA-positive metastatic castration-resistant prostate cancer who progressed on or after [177Lu]Lu-PSMA targeted therapy	Dr Ravindran Kanesvaran	NCT06780670	Open
51	Prostate	Metastatic/ mCRPC	CAAA817B12301 (AcTFirst) A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care inadult participants with PSMA-positive metastatic castration resistant prostate cancer	Dr Johan Chan	NCT06855277	Open
52	Prostate	Metastatic/ mCRPC	Amgen 20230239 A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Monotherapy, Xaluritamig Plus Abiraterone versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer	Dr Johan Chan	NCT07213674	Open
53	Prostate	Metastatic/ mCRPC	177Lu-TLX591-203 A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with Prostate-Specific Membrane Antigen (PSMA) Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) after Androgen Receptor Pathway Inhibitor (ARPI) Treatment	Dr Ravindran Kanesvaran	NCT06520345	Open
54	Prostate	Metastatic/ mCRPC	MK-2400-001 A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)	Dr Johan Chan	NCT06925737	Open
55	Renal	Advanced/ Metastatic	MK6482-033 A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants with Advanced RCC who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)	Dr Ravindran Kanesvaran	NCT07227402	Open

General

No	Site	Stage of cancer	Title of study	Principal investigator	Details of trial	Status
1	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	APL10101 Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Dr Gillianne Lai	NCT03175224	Open
2	SOLID TUMORS	LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line Onwards	TPX-0005-01 A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)	Dr Darren Lim	NCT03093116	Open
3	SOLID TUMORS	ADVANCED/ METASTATIC	Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations	Dr Joanne Ngeow	NCT04924075	Open